Tag: China
China’s surge in antibody-drug conjugates positions it as key oncology market,...
ADCs have become a focal point in oncology due to their ability to selectively target cancer cells, resulting in reduced off-target side effects.
Exclude medical devices from the list of India-EU Free Trade Agreement...
India already dependent on imports of medical devices to the tune of 70% presently
Does China’s leading place in the global MedTech market reflect the...
Naturally, given the potential riches on offer, many western MedTech multinationals are now tailoring their R&D and manufacturing strategies to align with the Chinese market's unique needs and government initiatives
Nasovac-S4 offers defence against recent surge in respiratory illnesses, say experts
NASOVAC-S4, India’s first exclusive needle-free flu vaccine, is administered through the nasal route, offering a non-invasive and painless alternative to traditional injections
Agri testing services market growth to enrich with better productivity &...
Future Market Insights states that Asia Pacific excluding Japan is anticipated to account for a significant share in the global agricultural testing services market from the forecast period 2023 to 2033
MTaI recommends Japan as the “China+1 alternative in MedTech imports
Increase in MedTech imports from China by 57% in FY 21-22 raise concerns
Chinese regulators focus on homegrown COVID-19 therapies to tackle new variants,...
According to GlobalData’s Pharma Intelligence Center, there are currently 16 COVID-19 drugs in clinical development in China, five of which are in Phase III
Vaccines with efficacy against Omicron variants will gain competitive advantage in...
According to GlobalData’s Pharma Intelligence Center, there are currently 19 COVID-19 vaccines in clinical development in China, with only 3 candidates in Phase III trials
NAFLD clinical trial activity catching up in China, mostly driven by...
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade
Heart attack diagnostics market sales create significant incremental opportunity over 2032
In the test sector, blood tests from the heart attack diagnostics market are anticipated to flourish at the quickest CAGR of 6.8% through 2032